Related Experiment Video
Updated: May 19, 2026
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Chemotherapy in low-grade gliomas.
Aurélien Viaccoz1, Alain Lekoubou, François Ducray
1Service de Neuro-Oncologie, Hôpital Neurologique, Hospices Civils de Lyon, Lyon, France.
Current Opinion in Oncology
|August 24, 2012
Summary
Chemotherapy offers a viable treatment for diffuse low-grade gliomas (LGGs), with significant radiological and clinical responses observed. Biomarkers like IDH1 mutation are emerging as predictors of chemotherapy effectiveness.
Area of Science:
- Neuro-oncology
- Clinical pharmacology
- Oncology
Background:
- Diffuse low-grade gliomas (LGGs) represent a significant challenge in neuro-oncology.
- Understanding treatment response and predictive biomarkers is crucial for optimizing patient outcomes.
Purpose of the Study:
- To review recent advancements in chemotherapy for adult diffuse low-grade gliomas (LGGs).
- To assess treatment response and identify potential predictive biomarkers for chemosensitivity.
Main Methods:
- Review of recent studies on chemotherapy for LGGs.
- Analysis of response assessment criteria and predictive biomarkers.
- Inclusion of data on radiological and clinical outcomes.
Main Results:
- Chemotherapy, including temozolomide and PCV regimens, shows radiological responses in 25-50% of LGG patients.
- Over half of patients experience clinical benefits, such as reduced seizure frequency.
- IDH1 mutation, alongside 1p/19q codeletion and MGMT methylation, may predict chemosensitivity.
Conclusions:
- Chemotherapy is an established treatment option for LGGs, but optimal use requires further investigation.
- Ongoing phase III studies will clarify the role of chemotherapy and the predictive value of biomarkers like IDH1 mutation.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...